Glutamic acid decarboxylase antibodies i
โ
Pasquale Striano; Giuseppe Perruolo; Luca Errichiello; Pietro Formisano; Frances
๐
Article
๐
2008
๐
John Wiley and Sons
๐
English
โ 49 KB
colleagues' concern that there may be bias toward patients with more progressive disease in the control group compared with the treated group appears unlikely. The 20% of patients in the control group who had discontinued immunomodulatory or immunosuppressive treatment in the first 3 to 6 weeks bec